单株抗体疗法市场规模、份额和成长分析（按生产方法、来源、治疗方法、给药方法、最终用户和地区划分）—2026-2033年产业预测

预计到 2024 年，单株抗体疗法市场规模将达到 1,653 亿美元，到 2025 年将达到 1,773.6 亿美元，到 2033 年将达到 3,116.4 亿美元，预测期（2026-2033 年）的复合年增长率为 7.3%。

全球单株抗体疗法市场的主要驱动力是癌症、自体免疫疾病和心血管疾病等慢性疾病发生率的不断上升。单株抗体在应对这些健康挑战方面的有效性使其在临床实践中广泛应用。此外，人口老化和文明病相关健康问题的日益增加也持续推动着市场成长。技术进步使得高特异性和高效率抗体的研发成为可能，提升了其治疗潜力。对个人化医疗和标靶治疗策略的日益重视也是推动单株抗体疗法需求的关键因素，使其成为现代医疗保健解决方案的重要组成部分。

单株抗体疗法市场驱动因素

生物技术和基因工程的进步极大地推动了单株抗体疗法的发展。这些领域的创新使得人们能够研发出特异性更高、疗效更佳、副作用更小的抗体。基因工程技术的应用使研究人员能够设计出有效针对特定疾病的单株抗体，从而拓展了其治疗潜力。这项进步不仅拓宽了单株抗体疗法的应用范围，也提高了治疗成功率，进而巩固了这些疗法在现代医学中的地位。

限制单株抗体疗法市场的因素

单株抗体疗法虽然有益，但并非没有挑战，因为它们可能引起多种副作用和安全问题。患者在接受治疗时可能会出现输注相关反应，程度从轻微到严重不等。此外，还存在免疫抗原性风险，即免疫系统对治疗产生不良反应。脱靶效应也可能发生，导致体内出现意想不到的相互作用。为了保障病人安全并维护对这些治疗方法的信心，必须进行全面的监测，实施严格的安全评估，并清楚传达潜在风险。有效管理这些问题对于确保患者健康和符合监管要求至关重要。

单株抗体疗法市场趋势

单株抗体疗法市场正朝着个人化和标靶治疗的引入和开发显着成长的方向发展。这一趋势的驱动力在于先进诊断技术、基因谱分析和生物标记识别的整合，使医疗服务提供者能够为每位患者量身定制治疗方案。这种策略性的个人化治疗能够提高疗效并最大限度地减少副作用，有助于改善癌症、自体免疫疾病和感染疾病等疾病的整体治疗效果。随着医疗保健格局的演变，对符合个人化医疗原则的单株抗体的需求持续增长，推动着生物製药产业的创新并重塑着治疗模式。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球单株抗体疗法市场规模（按产量和复合年增长率划分）（2026-2033 年）

• 体外
• In vivo

全球单株抗体疗法市场规模（按来源和复合年增长率划分）（2026-2033 年）

• 人类来源
• 人性化
• 嵌合体体
• 其他的

全球单株抗体疗法市场规模（依疗法划分）及复合年增长率（2026-2033 年）

• 自体免疫疾病与发炎性疾病
• 肿瘤学
• 血液学
• 眼科
• 其他的

全球单株抗体疗法市场规模（按给药途径和复合年增长率划分）（2026-2033 年）

• 静脉注射
• 皮下注射
• 其他的

全球单株抗体疗法市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 长期照护机构
• 其他的
• 全球单株抗体疗法市场规模及复合年增长率（2026-2033）
• 北美（生产、供应来源、处理、管理、最终用户）
  • 美国
  • 加拿大
• 欧洲（生产、来源、处理、管理、最终用户）
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区（生产、来源、处理、管理、最终用户）
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲（生产、来源、处理、管理、最终用户）
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲（生产、供应来源、处理、管理、最终用户）
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
• 2023-2025年营收年比比较

主要企业简介

• Zoetis Inc.（USA）
• Merck & Co., Inc.（USA）
• Elanco Animal Health Incorporated（USA）
• Boehringer Ingelheim International GmbH（Germany）
• Ceva Sante Animale（France）
• Virbac（France）
• Vetoquinol（France）
• Bayer AG（Germany）
• Novartis AG（Switzerland）
• Eli Lilly and Company（USA）
• Sanofi（France）
• Intervet Inc.（Netherlands）
• Alltech（Ireland）
• Huvepharma（Bulgaria）
• Kemin Industries（USA）
• Novus International（USA）
• Biomin Holding GmbH（Austria）
• ADM Animal Nutrition（USA）
• Adisseo（France）
• DSM（Netherlands）

结论与建议

Monoclonal Antibody Therapy Market size was valued at USD 165.3 Billion in 2024 and is poised to grow from USD 177.36 Billion in 2025 to USD 311.64 Billion by 2033, growing at a CAGR of 7.3% during the forecast period (2026-2033).

The global monoclonal antibody therapy market is significantly driven by the rising incidence of chronic diseases, including cancer, autoimmune disorders, and cardiovascular issues. The effectiveness of monoclonal antibodies in addressing these health challenges has led to their increasing acceptance in clinical settings. Furthermore, an aging demographic alongside the escalation of lifestyle-related health concerns continues to bolster market growth. Advances in technology have facilitated the development of highly specific and effective antibodies, enhancing their therapeutic potential. The growing emphasis on personalized medicine and targeted treatment strategies is also a key factor propelling the demand for monoclonal antibody therapies, positioning them as a vital component in modern healthcare solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Monoclonal Antibody Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Monoclonal Antibody Therapy Market Segments Analysis

Global Monoclonal Antibody Therapy Market is segmented by production, source, therapy, administration, end user and region. Based on production, the market is segmented into in vitro and in vivo. Based on source, the market is segmented into human, humanized, chimeric and other. Based on therapy, the market is segmented into autoimmune and inflammatory disorders,oncology, hematology, ophthalmology and others. Based on administration, the market is segmented into intravenous, subcutaneous and other. Based on end user, the market is segmented into hospitals, long term care facilities and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Monoclonal Antibody Therapy Market

The advancement of biotechnology and genetic engineering has significantly propelled the growth of monoclonal antibody therapies. Innovations in these fields have enabled the creation of antibodies that boast enhanced specificity, improved efficacy, and minimized side effects. With the application of genetic manipulation techniques, researchers are able to tailor monoclonal antibodies to effectively target specific diseases, thereby amplifying their therapeutic potential. This progress has not only expanded the possible uses for monoclonal antibody therapies but has also contributed to higher success rates in treatment outcomes, reinforcing the role of these therapies in modern medicine.

Restraints in the Monoclonal Antibody Therapy Market

Monoclonal antibody therapies, while beneficial, are not without their challenges, as they can lead to various side effects and safety issues. Patients may experience infusion-related reactions upon receiving the treatment, which can range from mild to severe. Additionally, there is the risk of immunogenicity, where the immune system reacts negatively to the therapy. Off-target effects may also arise, resulting in unintended interactions within the body. To safeguard patient safety and uphold trust in these therapies, it is essential to conduct thorough monitoring, implement strong safety assessments, and communicate potential risks clearly. Effectively managing these concerns is critical for ensuring patient well-being and complying with regulatory requirements.

Market Trends of the Monoclonal Antibody Therapy Market

The monoclonal antibody therapy market is experiencing a notable shift towards increasing adoption and development of personalized and targeted therapies. This trend is driven by the integration of advanced diagnostics, genetic profiling, and biomarker identification, enabling healthcare providers to customize treatments for individual patients. Such strategic personalization enhances therapeutic efficacy while minimizing adverse effects, thereby improving overall treatment outcomes for diseases like cancer, autoimmune disorders, and infectious diseases. As the healthcare landscape evolves, the demand for monoclonal antibodies that align with personalized medicine principles continues to grow, fueling innovation and reshaping treatment paradigms in the biopharmaceutical industry.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Monoclonal Antibody Therapy Market Size by Production & CAGR (2026-2033)

• Market Overview
• In Vitro
• In Vivo

Global Monoclonal Antibody Therapy Market Size by Source & CAGR (2026-2033)

• Market Overview
• Human
• Humanized
• Chimeric
• Other

Global Monoclonal Antibody Therapy Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Autoimmune And Inflammatory Disorders
• Oncology
• Hematology
• Ophthalmology
• Others

Global Monoclonal Antibody Therapy Market Size by Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous
• Other

Global Monoclonal Antibody Therapy Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Long Term Care Facilities
• Others
• Global Monoclonal Antibody Therapy Market Size & CAGR (2026-2033)
• North America (Production, Source, Therapy, Administration, End User)
  • US
  • Canada
• Europe (Production, Source, Therapy, Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Production, Source, Therapy, Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Production, Source, Therapy, Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Production, Source, Therapy, Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
• Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet Inc. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alltech (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma (Bulgaria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novus International (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomin Holding GmbH (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADM Animal Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adisseo (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DSM (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations